Charles Fracchia is the founder and CEO at BioBright, a company focusing on creating open, interoperable tools to revolutionize the process of biomedical research and provide a framework for more open science. He is on a leave of absence from the MIT Media Lab where he was an IBM PhD Fellow in Joe Jacobson’s Molecular Machines group, and jointly in the Church lab at the Wyss Institute at Harvard Medical School. Charles obtained his bachelor’s at Imperial College London, where he worked on a bioelectronic interface between engineered bacteria and electronic sensors. He continued his thesis work at IBM Research, where he has been encouraging research in the field ever since. Charles worked as an early intern at Ginkgo Bioworks, where he developed many of the automated assembly pipelines still used today. In 2016, he was named one of the 35 innovators under 35 by the MIT Technology Review.